Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.65 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 3/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075190 | 1.00 | NTRK1 (0.65) | NTRK1PAK4PAK1IGF1RSRC | |
| SCHEMBL4074989 | 0.94 | NTRK1 (0.64) | NTRK1PAK4PAK1IGF1R | |
| SCHEMBL27654586 | 0.94 | NTRK1 (0.64) | NTRK1PAK4PAK1IGF1R | |
| SCHEMBL4151812 | 0.90 | NTRK1 (0.70) | NTRK1PAK4PAK1IGF1RSRC | |
| SCHEMBL4551106 | 0.86 | NTRK1 (0.65) | NTRK1PAK4IGF1RGSK3B | |
| SCHEMBL4160193 | 0.86 | NTRK1 (0.65) | NTRK1PAK4IGF1RGSK3B | |
| SCHEMBL4075185 | 0.85 | NTRK1 (0.59) | NTRK1PAK4PAK1SRCCCNA2 | |
| SCHEMBL4074253 | 0.84 | NTRK1 (0.73) | NTRK1PAK4IGF1R | |
| SCHEMBL4155699 | 0.83 | NTRK1 (0.83) | NTRK1IGF1R | |
| SCHEMBL4151532 | 0.83 | NTRK1 (0.83) | NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| CN-1905884-A | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885PAK4 1337/4885PAK1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.